tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Foghorn Therapeutics CFO Kristian Humer Resigns
PremiumCompany AnnouncementsFoghorn Therapeutics CFO Kristian Humer Resigns
26d ago
Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
Premium
The Fly
Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
26d ago
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
Premium
Ratings
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
28d ago
Foghorn Therapeutics transferred with Buy rating at B. Riley
PremiumThe FlyFoghorn Therapeutics transferred with Buy rating at B. Riley
3M ago
Foghorn Therapeutics Advances in Precision Therapeutics
Premium
Company Announcements
Foghorn Therapeutics Advances in Precision Therapeutics
3M ago
Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
Premium
Ratings
Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
4M ago
Foghorn Therapeutics Faces Significant Business Risk: Potential Impact on Operations and Investor Confidence
PremiumCompany AnnouncementsFoghorn Therapeutics Faces Significant Business Risk: Potential Impact on Operations and Investor Confidence
4M ago
Foghorn Therapeutics Signs New Lease Agreement
Premium
Company Announcements
Foghorn Therapeutics Signs New Lease Agreement
5M ago
Foghorn Therapeutics Holds Successful Annual Meeting
Premium
Company Announcements
Foghorn Therapeutics Holds Successful Annual Meeting
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100